![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the award, Exvastat will collaborate with Vrije Universitat, Amsterdam Medical Center, KABS (Canada) and Simbec-Orion to produce a reformulated version of imatinib and test it in critically ill COVID-19 patients.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovative Medicines Initiative
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Funding May 15, 2020